Summary
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
The global Irritable Bowel Syndrome (IBS) market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

IBS-D Drug
IBS-C Drug
Others
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Women
Men

Company Coverage (Sales data, Main Products & Services etc.):

Valeant Pharmaceuticals
Allergan
Takeda
Sucampo Pharmaceuticals
McNeil Consumer Healthcare
Sebela Pharmaceuticals
Astellas Pharmaceuticals
IM HealthScience

Major Region

Market
North America
Europe
Asia-Pacific
South America
Middle East & Africa